New Monthly HIV Pill Could Reach Africa Faster Than Ever

For the first time in medical history, a pharmaceutical company is breaking its own rules to get life-saving HIV prevention medicine to people faster.

Merck just gave seven manufacturers permission to prepare factories for a new once-monthly HIV prevention pill called alimatravir, even though the final testing won't finish until late 2027. Three of those licenses went to African drug makers, including South Africa's largest pharmaceutical company, Aspen Pharmacare.

This unusual move means factories can set up production lines and train workers now, so they can start making pills the moment regulators give approval. Normally, this process only starts after approval, adding months or years of delay.

"We don't yet know if the medicine will work, so it's a risk that Merck is taking, but it's, in my opinion, a wise and strategically taken risk," Mitchell Warren from international HIV advocacy organization Avac said at the recent International AIDS Conference in Rio de Janeiro.

The pill could eventually cost as little as $4.50 per person per year to make. If approved, Aspen could sell it across all 54 African countries, potentially helping reduce South Africa's 140,000 new HIV infections each year.

But here's where the story gets even brighter. South Africa just discovered something powerful about HIV prevention, and it has nothing to do with which medicine works best.

In June, the country started offering a six-monthly HIV prevention injection called lenacapavir at 360 clinics, giving people a choice beyond the daily prevention pill. Before that, about 2,670 people per week started HIV prevention at over 4,500 clinics across the country.

After introducing the injection at just 360 clinics, that number jumped to 4,200 people per week. More people are now getting protected at fewer locations, simply because they have options.

The Ripple Effect

This mirrors what happened with birth control. When family planning programs offered multiple contraceptive methods instead of just one, far more people used protection. Different lives need different solutions.

The monthly pill offers yet another choice. Early testing shows it reaches protective levels within an hour of taking it, compared to seven days for the daily pill or three days for the injection when starting treatment.

Stavros Nicolaou from Aspen calls this development "a significant boost for Africa's pharmaceutical industrialization and regional manufacturing ambitions." Beyond preventing infections, it's building capacity for Africa to make its own medicines.

The pill belongs to a completely new class of HIV drugs that blocks the virus differently than existing options, giving scientists another tool in the prevention toolkit.

With three different prevention methods potentially available soon, millions more people across Africa may finally find an HIV prevention option that actually fits their life.